At a glance
ClinicalIndex Comparison RecordN/ACompleted· 125 enrolled
Drug / intervention
Visian TICLdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-Approval Study of the Visian Toric Implantable Collamer Lens
In Brief
A clinical study evaluating Visian TICL for Myopic Astigmatism. Completed, enrolled 125 participants across 8 sites.
Detailed Summary
The objective of this study is to evaluate the long term (i.e. 24 months) clinical performance of the Visian® Toric Implantable Collamer® Lens (ICL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyopic Astigmatism
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartJul 2020
First PostedAug 2020
Primary CompletionDec 2024
TodayJul 2026
First PostedAug 18, 2020
Enrollment StartJul 21, 2020
Primary CompletionDec 11, 2024
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 5.9 years ago
Interventions
Visian TICLdevice
The Visian TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.